新的WHO分类影响临床治疗策略--对炎性肌纤维母细胞瘤的重新认识

目的探讨新的WHO软组织肿瘤分类制定后,对炎性肌纤维母细胞瘤的组织学诊断特点和外科治疗观念的更新。方法对我科收治的4例手术病理确诊为炎性肌纤维母细胞瘤(炎性假瘤)患者的临床资料进行分析,并结合文献复习。结果2例就诊于新的WHO软组织肿瘤分类制定前的患者,其治疗按良性肿瘤对待;2例就诊于新分类制定后的患者,其治疗按低度恶性肿瘤对待。结论新的WHO分类认为炎性肌纤维母细胞瘤是真性肿瘤,少数可转移,属低度恶性,其治疗由以往的单纯肿物切除变为适当扩大切除范围。

New WHO Classification Changing the Strategy of Clinical Treatment--A Recognition of Inflammatory Myofibroblastic Tumor

Objective To update the recognition of histological character of inflammatory myofibroblastic tumor and surgical treatment after the new WHO classification was introduced.Methods Analyze the data of the four patieats with inflammatory myofibrob lastic tumor and review the relative literatures.Results The two patients diagnosed before the new WHO classification can be treated as carcinoid ones,as for the other two patients diagnosed after the classification,they can be treated as low grade malignancy.Conclusion The new WHO classification supports that the inflammatory myofibroblastic tumor is real tumor,with low grade malignancy,the scope of the tumor's excision should be enlarged.